Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay
Journal of Pharmaceutical Analysis · 2025-12 · 15 (12) · 101318
DOI: 10.1016/j.jpha.2025.101318 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical Analysis, 2025-12. Verfasst von Ming Gu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Natural Science Foundation.
Abstract (Originalsprache)
Evidences indicate that farnesoid X receptor (FXR) activation mitigates non-alcoholic fatty liver disease (NAFLD) by reducing endoplasmic reticulum (ER) stress. However, the mechanisms underlying FXR-ER stress interactions in combating NAFLD remain obscure. Moreover, few phytochemicals have been noted to improve NAFLD through this pathway. Here, we found that FXR activation directly induces the transcription of sarco/endoplasmic reticulum Ca2+ ATPase 2 (SERCA2), which acts as an ER stress repressor. This process leads to the dephosphorylation of the eukaryotic translation initiation factor 2 subunit α (eIF2α) within hepatocytes, consequently alleviating ER stress. Furthermore, through drug binding assays, luciferase reporter gene testing, gene expression analysis and biochemical evaluation, we identified the phytochemical atractylenolide II (AT-II) as a novel FXR agonist that effectively triggers SERCA2 activation. Our results showed AT-II effectively supresses accumulation of lipids and ER stress in palmitic acid-induced hepatocytes. In in vivo experiments, we demonstrated that AT-II attenuates fatty liver in diet- or chemical-induced NAFLD mouse models. Additionally, we showed that AT-II corrects diet-induced obesity, serum dyslipidemia, metabolic complications, and insulin resistance. Mechanistically, AT-II reduces ER stress, lipogenesis and inflammation and improves hepatic insulin signaling through stimulation of the hepatic FXR-SERCA2-eIF2α axis in mice. This conclusion was further reinforced by Serca2 knockdown both in vivo and in vitro, as well as FXR silencing in hepatocytes. Our findings provide new insights into the FXR-ER stress interplay in the control of NAFLD and suggest the potential of AT-II as an FXR agonist for the treatment of NAFLD through SERCA2 activation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Digestive Disease, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China.
- School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
Förderung
- Shanghai Municipal Natural Science Foundation
Zitieren
APA
Gu, M., Chen, Z., Chen, Y., Li, Y., Wang, H., Feng, Y. R., Zheng, P., & Huang, C. (2025). Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay. Journal of Pharmaceutical Analysis, 15(12), 101318. https://doi.org/10.1016/j.jpha.2025.101318
Vancouver
Gu M, Chen Z, Chen Y, Li Y, Wang H, Feng YR, et al. Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay. Journal of Pharmaceutical Analysis. 2025;15(12):101318. doi:10.1016/j.jpha.2025.101318
BibTeX
@article{Gu2025,
author = {Gu, Ming and Chen, Zhiwei and Chen, Yujun and Li, Yiping and Wang, Hongqing and Feng, Ya-Ru and Zheng, Peiyong and Huang, Cheng},
title = {Unlocking the potential of atractylenolide II: Mitigating non-alcoholic fatty liver disease through farnesoid X receptor-endoplasmic reticulum stress interplay},
journal = {Journal of Pharmaceutical Analysis},
year = {2025},
volume = {15},
number = {12},
pages = {101318},
doi = {10.1016/j.jpha.2025.101318}
}
EUVIMED